[ad_1]
The new corona pneumonia vaccine developed jointly by AstraZeneca and the University of Oxford has an average protective effect of 70%. Although the effect is not as good as that of the competitors, the researchers still chanted that it is a “vaccine for the world.” Due to lower prices, convenient transportation, and faster production increases, you can benefit more people around the world.
Barron’s, CNBC and Reuters reported that AstraZeneca announced on the 23rd that, depending on the injection dose, there were two results in the vaccine trial. 8,900 volunteers participated in a large-scale trial, two doses of the vaccine were administered one month apart, and the protective effect was 62%. In another series of trials, 2,700 volunteers participated, they were vaccinated with a half dose of the vaccine and after a month’s interval they were given another dose of the vaccine, with a protective effect of 90%. Combining the results of the two groups, the mean protective efficacy of the vaccine is 70%.
The AstraZeneca vaccine is less effective than its opponents, the Pfizer vaccine has a 95% protective effect and Moderna has 94.5%. But this result is good enough and many commercially approved vaccines are just as effective.
Although the protective effect is slightly less, Jefferies noted that the AstraZeneca vaccine has advantages in price, storage and distribution. This vaccine can be stored for at least 6 months in a normal refrigerator (36 ~ 46 ° F, 2 ~ 8 ° C). The pharmaceutical factory promised to sell it at cost price during the epidemic, the price per dose is rumored to be between US $ 3 and US $ 4, which is much lower than that of the industry.
As a control, Moderna should be stored at a low temperature of -4 degrees Fahrenheit (-20 degrees Celsius) for 6 months, and the price per dose is as high as $ 32-37. Pfizer / BioNTech vaccines must be stored at a super low temperature of -94 degrees Fahrenheit (-70 degrees Celsius), which requires special cold chain transport and storage devices, and the price per dose is US $ 20.
Deutsche Bank strategists said the optimism of the AstraZeneca vaccine is a “big deal.” This vaccine is cheap and easy to store. It is particularly important for low- and middle-income countries. Emerging markets are a great beneficiary, including Brazil, Mexico, India, Indonesia, etc.
AstraZeneca stated that it can produce up to 200 million doses of vaccine by the end of this year, which is four times the number of Pfizer vaccines. And there will be 700 million doses of the AstraZeneca vaccine globally in the first quarter of next year at the earliest. Andrew Pollard, director of the Vaccine Group at the University of Oxford, said: “This means that we have a vaccine available globally.”
(This article is reprinted with permission from MoneyDJ News; source for first image: AstraZeneca)
Further reading:
New knowledge of science and technology, always updated
[ad_2]
